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a  b  s  t  r  a  c  t
Paraquat  poisoning  resulted  in  multiorgan  failure  and  is  associated  with  high  mortality.  We
audited 83  historical  cases  of  paraquat  poisoning  in past  2 years  treated  with  conventional
decontamination  and  supportive  treatment,  followed  by enrolling  85  patients  over  a  2  year
period  into  additional  immunosuppression  with  intravenous  (i.v.)  methylprednisolone  and
i.v. cyclophosphamide.
Our results  showed  that  age,  poor  renal  function  and  leucocytosis  are  the  main  predictors
of  fatal  outcome.  Immunosuppression  regime  rendered  higher  survival  (6 out of  17 patients
(35.3%))  versus  historical  control  (1 out of  18 patients  (5.6%))  (p  = 0.041)  in  the  cohort  with
admission  eGFR  < 50  ml/min/1.73  m2 and  WBC  count  > 11,000/L.
In contrast,  there  was  no difference  in survival  with  immunosuppression  regime  (38
out of 64  patients  (59.4%))  compared  to historical  control  (30  out of 52 patients  (57.7%))
(p  = 0.885)  in those  with  eGFR  >  50 ml/min/1.73  m2 or WBC  < 11,000/L  at presentation.
Multivariable logistic  regression  showed  survival  probability  = exp(logit)/(1  +  exp(logit)),
in which  logit  = 13.962 −  (0.233 × ln(age  (year)))  −  (1.344  × ln(creatinine  (mol/L)))  −
(1.602 × ln(rise  in creatinine  (mol/day)))  –  (0.614  × ln(WBC  (,000/L)))  +  (2.021  ×
immunosuppression) and  immunosuppression  = 1 if given  and  0 if not. Immunosup-
pression  therapy  yielded  odds  ratio  of 0.132  (95%  conﬁdential  interval:  0.029–0.603,
p  =  0.009).In  conclusion,  immunosuppression  therapy  with  intravenous  methylprednisolone  and
cyclophosphamide  may  co
ing and  improve  survival
count  >  11,000/L.
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. Introduction
Paraquat poisoning could result in multiorgan failure.
esides intestinal decontamination [1,2], the administra-
ion of glucocorticoids and cyclophosphamide has been
dvocated following the study by Lin et al. [3,4]. Because
f  constructive appraisal on the actual efﬁcacy of immuno-
uppression [5], Lin et al. subsequently performed a
andomized controlled trial of 23 patients with paraquat
oisoning, with measurement of plasma paraquat levels.
he  study showed that the mortality rate was 31.3% in the
reatment arm versus 85.7% in the control arm (p = 0.0272)
6].  Another study done in Iran showed similar trend in
utcome [7] favouring the use of cyclophosphamide. Nev-
rtheless,  to our knowledge, there is not yet any study
dentifying the speciﬁc group that may  beneﬁt most from
mmunosuppression therapy. This in fact is an important
iece of information, because one has to ascertain the
otential beneﬁt for each patient based on their clinical
roﬁle and decides the more suitable modality of treat-
ent, whether to utilize larger dose of immunosuppression
r to omit immunosuppression therapy.
. Methods
This is a multicentre clinical trial performed in Min-
stry of Health Hospitals in Kuching, Miri, Sibu, Ipoh, Sungai
etani  and Seremban cities.
The  inclusion criteria were:
.  History of recent paraquat ingestion within 3 days prior
to admission.
. Positive urine paraquat test, or presence of any feature
of systemic paraquat toxicity involving kidney, liver or
lungs.
We  excluded those subjects who were pregnant.
All patients were treated with intestinal decontami-
ation (Appendix I) (23) and IV hydration. We enrolled
5  cases of paraquat poisoning in Years 2011 and 2012
nto  an immunosuppression protocol (Appendix II), com-
rising  of IV methylprednisolone (1 g/day) for ﬁrst 3
ays  (adjustment if needed in liver impairment) and IV
yclophosphamide (15 mg/kg/day) for ﬁrst 2 days (adjust-
ent  if needed in acute kidney failure).
Their clinical proﬁle and outcome were compared with
istorical cohort of 83 cases of paraquat poisoning in the
ast  2 years (Years 2009–2010).
This  study was approval by Malaysian National Medi-
al  Research Ethical Committee (NMRR-11-587-9673) and
nformed  consents were taken from patients. Outcome was
eriﬁed  by clinical notes and follow-up phone calls.
Paraquat was tested qualitatively with sodium bicar-
onate and sodium dithionite. We  estimated eGFR using
he  MDRD formula [10].
Our approaches in the analysis were:) Compare the clinical proﬁle between subjects with
immunosuppression therapy versus historical cohort.
) Identify the predictors for survival.orts 1 (2014) 490–495 491
c)  Evaluate if these survival predictors affect the efﬁcacy of
immunosuppression in terms of survival.
The  statistical data were analysed using Microsoft excel
and  SPSS 15 (Statistical Package for Social Science, SPSS Inc.,
Chicago,  IL).
Only  patients with complete data were included for
analysis to derive the ﬁnal output for statistical tables and
ﬁgures.
Kolmogorov–Smirnov test was  initially used to deter-
mine whether the data is in statistical normal distribution
and subsequently logarithm transformation would be per-
formed  as necessary [11]. These would be followed by
appropriate parametric or non-parametric test as well as
parameter description: mean ± standard deviation.
Univariate analysis was performed with parametric test
(e.g.,  Student’s t-test, ANOVA) for survival comparison in
data  with statistical normal distribution and geometric
transformation was  performed as necessary. Factors that
signiﬁcantly affect the predictor and survival were ana-
lysed  with ANCOVA test.
Chi  square test and Fisher’s exact test will be utilized
according to the standard statistical procedure.
Finally we  apply logistic regression to identify the risk
predictors and use these factors to identify the patients that
beneﬁt  best from immunosuppression.
3.  Results
3.1. Comparison of baseline clinical parameters between
the  subjects with immunosuppression therapy and
historical cohort
There  were no signiﬁcant differences in clinical param-
eters on admission between the two groups (Table 1).
3.2.  Identiﬁcation of survival predictors
Table 2 and Fig. 1A and B showed overall better survival
in  patients with higher eGFR (estimated glomerular ﬁl-
tration  rate), low serum creatinine, slower creatinine rise,
lower  white blood cell (WBC) count, higher serum bicar-
bonate  (HCO3), besides traditional predictors of younger
age  and smaller amount of paraquat ingestion.
3.3. Evaluation of the efﬁcacy of immunosuppression in
groups  with various survival predicting parameters
Comparing the two groups overall, there was  mild sur-
vival  beneﬁt with 44 over 85 immunosuppression groups
(52%),  versus 38 over 83 historical controls survived (46%)
(p  = 0.438).
However, in cohort with eGFR < 50 ml/min/1.73 m2 and
WBC  count > 11,000/L at presentation, immunosuppres-
sion regime rendered signiﬁcantly higher survival rate (6
out  of 17 patients (35.3%)) when compared to historical
control (1 out of 18 patients (5.6%)) (p = 0.041) (Fig. 2).
Nevertheless, there was no difference in survival with
immunosuppression regime (38 out of 64 patients (59.4%))
compared to historical control (30 out of 52 patients
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Table  1
Univariate analysis: comparison of clinical parameters during admission between subjects in immunosuppression arm and historical cohort.
N Mean immunosuppression Historical cohort p-value
Age Year 159 30 ± 14 34 ± 17 NS
Gender a F:M 168 33:52 33:50 NS
Vomit a Y:N 127 67:9 43:8 NS
Duration from paraquat ingestion to admission h 153 10.2 ± 15.8 17.0 ± 41.7 NS
Amount of paraquat concentrate ingested ml 143 164 ± 224 127 ± 162 NS
Creatinine mol/L 162 153 ± 175 176 ± 152 NS
Initial rise in creatinine mol/L per day 121 113 ± 136 78 ± 179 NS
eGFR ml/min/1.73 m2 154 80 ± 43 64 ± 45 NS
Urea mmol/L 167 5.9 ± 6.5 7.1 ± 9.3 NS
Total bilirubin mol/L 151 15.3 ± 12.6 28.0 ± 53.8 NS
Conjugated bilirubin mol/L 81 7.8 ± 14.2 3.8 ± 5.0 NS
AST U/L 141 108 ± 366 60 ± 77 NS
ALT U/L 150 82 ± 244 46 ± 91 NS
WBC  ,000/L 156 12.6 ± 4.3 14.7 ± 7.4 NS b
HCO3 mmol/L 127 20.9 ± 4.8 19.8 ± 5.1 NS
PaO2 mmHg 126 94 ± 31 88 ± 28 NS
l distribAbbreviation: NS, not signiﬁcant.
Univariate  analysis was performed with Student’s t-test.
a Chi square test was  performed for gender in univariate analysis.
b Logarithm transformation was performed to achieve Gaussian norma
(57.7%)) (p = 0.885) in those with eGFR > 50 ml/min/1.73 m2
or WBC  < 11,000/L at presentation.
In  Table 3, multivariable logistic regression yielded sur-
vival  probability = exp(logit)/(1 + exp(logit)),
S  = e
logit
1 + elogit
Probablity of survival = elogit/(1 + elogit), in which
logit = 13.962 − (0.233 × ln(age (year))) − (1.344 × ln(crea-
tinine (mol/L))) − (1.602 × ln(rise in creatinine (mol/
day))) − (0.614 × ln(WBC (,000/L))) + (2.021 × immunos-
uppression) and R2 = 0.460 and immunosuppression = 1 if
given  and 0 if not.
Alternatively, logit = 5.923 − (0.203 × ln(age)) + (0.014
× eGFR) − (1.383 × ln(rise in creatinine)) − (0.775 ×
ln(WBC)) + (1.887 × immunosuppression) and R2 = 0.437.
Table 2
Univariate analysis: comparison of clinical parameters during admission in surviv
N M
Age Year 159 2
Gender c F:M 168 4
Vomit c Y:N 127 5
Duration from paraquat ingestion to admission h 153 9
Estimated amount of paraquat concentrate ingested ml 143 8
Creatinine on admission mol/L 162 1
Rise in creatinine within 24 h mol/L per day 121 3
eGFR ml/min/1.73m2 154 9
Urea mmol/L 167 4
Total bilirubin mol/L 151 1
Conjugated bilirubin mol/L 81 4
AST  U/L 141 4
ALT  U/L 150 3
WBC  ,000/L 15.6 1
HCO3 mmol/L 127 2
PaO2 mmHg 126 9
Unadjusted univariate analysis was performed with Student’s t-test. Note: male su
(192  ± 221 vs 77 ± 129 ml,  p < 0.001).
a Univariate adjusted analysis with ANCOVA were performed with age, if the u
b Univariate adjusted analysis with ANCOVA were performed with age and es
t-test  demonstrated signiﬁcant differences.
c Chi square test was  performed for gender in univariate analysis.ution, because of two subjects with extreme leucocytosis > = 35,000/L.
Immunosuppression therapy yielded odds ratio of 0.132
versus  historical cohort management without immuno-
suppression (95% conﬁdential interval: 0.029–0.603,
p = 0.009).
Only 21 subjects have undergone haemodialysis.
Among them, 15 subjects have haemodialysis within ﬁrst
day  after ingestion of paraquat and 6 survived (40%). In con-
trast,  out of 153 subjects who  have no haemodialysis within
a  day after paraquat ingestion, 77 survived (50%, p = 0.445).
4.  DiscussionParaquat poisoning results in multiorgan failure with
pulmonary ﬁbrosis, acute renal failure, liver impairment
and is associated with high mortality. Besides intesti-
nal decontamination [12], immunosuppression has been
ed and fatal patients in all subjects.
ean survived Fatal p-value
non-adjusted
p-value
adjusted a
p-value
adjusted b
9 ± 15 35 ± 15 0.011
1:41 21:65 0.005 0.022 0.294
0:10 60:7 0.304
.1 ± 16.4 17.4 ± 39.6 0.093
9 ± 139 201 ± 229 <0.001 0.002
03 ± 76 221 ± 201 <0.001 <0.001 <0.001
0 ± 71 178 ± 187 <0.001 <0.001 <0.001
3 ± 41 54 ± 40 <0.001 <0.001 <0.001
.6 ± 3.5 8.4 ± 10.3 0.002 0.003 0.034
5.3 ± 12.6 28.0 ± 53.8 0.048 0.073
.8 ± 9.2 7.2 ± 12.6 0.325
8 ± 79 122 ± 373 0.108
9 ± 60 92 ± 261 0.084
1.1 ± 3.4 16.0 ± 7.1 <0.001 <0.001 <0.001
2.2 ± 4.4 19.0 ± 4.8 <0.001 <0.001 <0.001
4 ± 27 89 ± 32 0.377
bjects has consumed higher amount of paraquat concentrate than female
nadjusted analysis by t-test demonstrated signiﬁcant differences.
timated amount of paraquat consumption, if the unadjusted analysis by
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Table 3
Logistic regression models to assess immunosuppression treatment response.
Parameters Per unit
increment
 for
survival
  for fatal Odds ratio 95% CI p-value 2 p-value
Lower bound Upper bound
Model with creatinine
R2 = 0.460 (n = 87)
All patients
Intercept  13.962 −13.962 0.001 14.2 0.000
ln(age) Year −0.233 0.233 1.262 0.286 5.573 0.759 0.1 0.759
ln(creatinine) mol/L −1.344 1.344 3.835 1.489 9.881 0.005 9.0 0.003
ln(rise in creatinine) mol/L/day −1.602  1.602 4.963 2.290 10.757 0.000 30.4 0.000
ln(white blood cell) ,000/L −0.614 0.614 1.847 0.343 9.936 0.475 0.5 0.474
Immunosuppression 2.021 −2.021 0.132 0.029 0.603 0.009 8.5 0.003
Overall model 53.6 <0.001
Model with eGFR
R2 = 0.437 (n = 86)
All patients
Intercept  5.923 −5.923 0.102 2.8 0.093
ln(age) Year −0.203 0.203 1.226 0.294 5.110 0.780 0.1 0.780
eGFR ml/min/1.73 m2 0.014 −0.014 0.986 0.973 0.999 0.030 5.3 0.021
ln(rise in creatinine) mol/L/day −1.383 1.383 3.988 2.032 7.829 <0.001 26.4 <0.001
ln(white blood cell) ,000/L −0.775 0.775 2.170 0.414 11.373 0.359 0.8 0.359
Immunosuppression 1.887 −1.887 0.152 0.036 0.637 0.010 8.0 0.005
Overall model 49.3 <0.001
Abbreviation: CI, conﬁdence interval.
Fig. 1. (A) Estimated glomerular ﬁltration rate (eGFR) on admission.
Standard deviation (SD) of 81 fatal cases versus 73 survived cases was
shown. (B) White blood cell (WBC) count on admission. Standard devia-
tion (SD) of 78 fatal cases versus 78 survived cases was  shown.Fig. 2. Survival in various cohorts of eGFR and WBC  count on admission.
advocated over the past 1–2 decades by many toxicology
experts and has demonstrated potential survival bene-
ﬁts  [3–9]. Subsequently a meta-analysis without serum
paraquat level as comparators [8,9] had shown potential
survival beneﬁt with concurrent use of glucocorticoid and
cyclophosphamide. However, none of these studies iden-
tify  the subgroup of subjects that may beneﬁt most from
immunosuppression therapy.
As consistent with previous studies [5], our study
demonstrated that renal function and WBC  at presenta-
tion were the key factors that inﬂuence outcome. These
parameters served as important tools and might potentially
act  as survival predictors besides the serum paraquat level
[12,13].  Besides these, the traditional markers, i.e., age and
amount  of paraquat consumption are still relevant factors
in  survival prediction [14].
Renal function at presentation is an important predictor
of  survival and we  wish to postulate that the signiﬁcance
of renal function might be due to (1) worse renal function
at  presentation or faster deterioration of renal function sig-
niﬁes  greater degree of paraquat intoxication or paraquat
induced inﬂammation. (2) Paraquat is excreted renally and
impaired  renal function results in reduced excretion of
logy Rep494 K.-H. Koh et al. / Toxico
paraquat and greater toxicity. Our study looked at the effect
of  immunosuppression in the group with poor renal func-
tion  and high WBC  and showed that immunosuppression
renders survival beneﬁt in this group of patients, whereas
there was no survival differences in the group with bet-
ter  preserved renal function and lower WBC. This suggests
that  immunosuppression may  counteract immune medi-
ated  inﬂammation after paraquat poisoning and this is
most  signiﬁcant in those with diminished renal function
and  leucocytosis. The fact that it did not affect the sur-
vival  in those with preserved renal function and lower
WBC  suggests that there may  be other mechanism of
damage besides immune mediated injury in paraquat poi-
soning.
Overall  in our series, the survival is still not opti-
mal  despite immunosuppressive therapy, other treatment
modality need to be explored to try to improve survival. As
acute  renal failure of paraquat poisoning is presumably an
oxidative  stress disorder [15], desferrioxamine may be use-
ful  in its treatment. In oxidative stress, lipid peroxidation
may  be enhanced by iron radicals, and chelating agent des-
ferrioxamine has been shown to reduce toxicity in animal
model  [16]. Desferrioxamine was used in the management
of  a single patient with severe paraquat intoxication, in
combination with decontamination, haemodialysis, and N
acetylcysteine with good outcome [17]. Desferrioxamine
was also included in the paraquat poisoning protocol in a
study  report in Korea [15].
Besides  haemoperfusion, as paraquat could be removed
by  dialysis because of its low molecular weight (257 g/mol),
extracorporal elimination might be worthwhile in early
phase,  including haemodialysis and haemoﬁltration. Nev-
ertheless,  various studies show variable and even contrary
results for all these modalities [18–20]. Wide volume of
distribution of paraquat in body tissues 1.2–1.6 L/kg [21]
and  potential of transient renal function reduction might
be  the reason of limitation of efﬁcacy in these modalities.
Besides, it might be hard to organize haemoﬁltration and
haemoperfusion in good timing in district hospital in rural
area.
Besides  exploring other treatment options such as des-
ferrioxamine, N acetyl cysteine, dialysis or haemoﬁltration,
a change in policy regarding usage of paraquat, dilution
of  paraquat is also a potential tool to further reduce the
mortality [22–24].
In  conclusion, paraquat poisoning is still associated with
very  high mortality rate with our current treatment regi-
men.  Renal function and leucocyte count on admission may
be  practical clinical parameters to help predict survival
and response to immunosuppression therapy. Immuno-
suppression with intravenous methylprednisolone and
cyclophosphamide might potentially improve patient sur-
vival  especially in those with eGFR < 50 ml/min/1.73 m2
and WBC  count > 11,000/L at presentation.
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Appendix  I. Paraquat poisoning management.
Modiﬁed from Sarawak Handbook of Medical
Emergencies 2nd and 3rd edition [2] with
permission
1. Insert nasogastric tube.
2. Stomach washout as soon as possible.
3.  Administer 300 ml  of Fuller’s earth via NG tube as soon
as possible, then 20 ml  of Fuller’s earth every hour until
diarrhoea and passage of Fuller’s earth.
4.  Magnesium sulphate (Mist alba) 30 ml  every 4 h for until
diarrhoea and passage of Fuller’s earth.
5.  Give 50 g of activated charcoal stat, then 25 g 4 h for sev-
eral days.
6. IV ﬂuids approx. 4–5 L/day (NS and D5%) for the ﬁrst 24 h,
then approx. 3 L/day orally or IV subsequently for several
days. In established renal failure, IV or oral ﬂuids should
be administered according to the ﬂuid status and urine
output.
7. Potassium supplement either IV or orally depending on
BUSE.
8. Frusemide 40 mg  bd IV or oral for several days.
9. Haemodialysis or charcoal haemoperfusion may  be use-
ful if started early, especially within 5–7 h of ingestion.
Appendix II. Immunosuppression protocol for the
management of paraquat poisoning
1. Pulse therapy with IV methylprednisolone (1 g/day) for
ﬁrst 3 days (adjustment: 500 mg/day if patient weight
is <40 kg, or if liver impairment developed).
2. However if IV methylprednisolone is not available upon
diagnosis in District Hospital, District Medical Ofﬁcer
could give iv hydrocortisone 200 mg  stat and send
patient to referral centre for 3 days of IV methylpred-
nisolone.
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. IV cyclophosphamide (15 mg/kg/day) for ﬁrst 2 days
(adjustment might be needed if renal impairment devel-
oped).
. If patient developed renal failure or PaO2 < 10.7 kPa
(80 mmHg), to switch to IV or oral dexamethasone 16
or 24 mg  daily after pulse methylprednisolone, and stop
when renal function improving and PaO2 > 80 mmHg.
. Consider repeat pulse therapy with methylprednisolone
(1  g/day for 3 days) if PaO2 was <8.0 kPa (60 mmHg) or
patient is deteriorating without other explainable rea-
son. Additional IV cyclophosphamide (15 mg/kg/day for
1 day) could be considered if renal function is normal
but respiratory function gets worse.
.  Watch out for concurrent infection.
.  If urine paraquat positive and urine output reduced
<100 ml/h even with hydration, start haemodialysis as
soon as possible for 4 h, Qb 300 ml/min, Qdialysate
500  ml/min and continue daily haemodialysis until urine
paraquat is negative.
. Immunosuppression should be initiated as early as pos-
sible without waiting for dialysis.
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